CEO Talks – The Buzz Immuno-Oncology
January 25 @ 4:00 pm - 7:00 pm
INFORM – ENGAGE – INSPIRE
BioBuzz has partnered with WSGR to launch a brand new BioHealth Capital Region event series that will focus on highlighting our region’s strongest technology assets while bringing you insights from local CEO’s on the game-changing technologies they are bringing to market.
Join us for this first event of this series and hear from an all-star panel of CEOs from three of the hottest companies in immuno-oncology. Our speakers will discuss the promises and challenges they face as their companies bring new therapies to the bedside. I-O is the future of oncology and these CEOs are making their mark in the field, each with a different (sp) approach. We will dive deep with these four cutting-edge and diverse technologies to show how they are utilizing the immune system to combat cancer.
- Jeff Galvin – Founder and CEO, AGT
- Bill Hearl – Founder and CEO, ITI
- Dr. Paul C. Tumeh – co-founder and CEO of BioGraph 55, Inc.
- Moderator – Charles Andres, Phd, RAC – Associate at Wilson Sonsini Goodrich & Rosati
3:30 pm – Arrival
4:00 pm – Discussion and Q&A
5:30 – 7:00 pm – Networking & refreshments
Guests are invited to stay after the discussion to continue the conversation with our panelists and other guests in true BioBuzz style, over refreshments. Tours of Montgomery College’s “better-than-pharma” labs and facilities will also be offered to those interested.
BioBuzz does not charge membership fees and rarely charges for our events. The CEO Talks series however will be by invitation only, which you can recieve from one of our Event Sponsors or our Annual Sponsors (see below). If you’ve received an invitation, please register below with your registration code and we look forward to seeing you at what will be a great evening of discussion and networking in the BioHealth Capital Region.
Meet our Panelists:
Bill Hearl – Founder and CEO, Immunomic Therapeutics
Dr. Bill Hearl is the Founder and Chief Executive Officer of Immunomic Therapeutics, Inc. (“ITI”). He is an experienced and successful scientific businessman and bio-entrepreneur, having founded both ITI and formerly Capital Genomix in 2000. Dr. Hearl has moved ITI steadily forward from an initial license agreement with the Geron Corporation in 2006 to an animal health license in 2012 and then most recently to two license deals with Astellas Pharma for the treatment of allergies, one for Japanese red cedar and a second global allergy license. The second deal brought ITI an upfront payment of $300,000,000 and established the Company as one of the leading entities in nucleic acid research. Dr. Hearl funded the Company by following a strategy of seeking a series of angel investment rounds which raised in aggregate over $12 million to drive the development of its allergy products. Prior to founding ITI and Capital Genomix, he was a senior executive at Kirkegaard & Perry Labs and then held various R&D positions at Life Technologies and Pharmacia. Dr. Hearl holds a Ph.D. in Biochemistry from the University of Tennessee (Oak Ridge & Knoxville) and holds multiple patents in the field of gene immunization.
Jeff Galvin – Founder and CEO, American Gene Technologies
Jeffrey A. Galvin is the CEO and Founder of American Gene Technologies™ (AGT). He earned his BA degree in Economics from Harvard in 1981 and has more than 30 years of business and entrepreneurial experience including founder or executive positions at a variety of Silicon Valley startups. Several of his companies were taken public and/or sold to public companies, including one in the medical-technology arena that was sold to Varian, the leading maker of linear accelerators used in cancer therapy. Following his startup experience, he retired to become an Angel Investor in real estate and high tech. He came out of retirement to found and fund AGT after meeting Roscoe Brady at NIH.
Dr. Paul C. Tumeh – Co-Founder and CEO of BioGraph 55, Inc.
Dr. Paul C. Tumeh is co-founder and CEO of BioGraph 55, Inc., an early-stage immuno-oncology target discovery and drug development company focused on targeting tumor-induced suppressive pathways expressed in T-cell inflamed, PD-L1 positive solid tumor types. Previously, Paul was an Assistant Professor at UCLA Medical Center and served patients with advanced melanoma. On the clinical side, he was a sub-investigator for all immunotherapy-focused Phase I/II clinical trials under the leadership of Antoni Ribas, MD, PhD. On the lab side, his translational immunology program focused on understanding how cellular interaction networks evolve during PD-1 blockade in responders versus progressors. His scientific contributions include publications in Nature and New England Journal of Medicine.
Moderator – Charles Andres, Phd, RAC – Associate at Wilson Sonsini Goodrich & Rosati
Charles Andres, Ph.D., RAC, is an associate in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati. He focuses on patent prosecution, strategic patent counseling, IP due diligence, drug and medical device FDA regulatory counseling, invalidity and non-infringement opinions, life-cycle management, Supreme Court and Federal Circuit amicus briefs, and related business matters. Prior to becoming a patent professional, Charlie spent a decade as a medicinal chemist and early-phase project co-chair at Bristol-Myers Squibb Company, where he won a Presidential Award, among other accolades. He holds Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professionals Society.
Please contact BioBuzz or a representative from one of our Sponsors for information on attendance.